Windlas Biotech (NSE:WINDLAS) Inventories, Finished Goods: ₹382 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
90 GF Score
Price ₹852.25
GF Value ₹940.70
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Inventories, Finished Goods?

Windlas Biotech NSE:WINDLAS +2.69% 90 Inventories, Finished Goods is ₹382 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 90/100 and a GF Value™ of ₹940.70 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's quarterly finished goods stayed the same from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹382 Mil).

Windlas Biotech's annual finished goods increased from Mar. 2024 (₹218 Mil) to Mar. 2025 (₹452 Mil) but then declined from Mar. 2025 (₹452 Mil) to Mar. 2026 (₹382 Mil).

Windlas Biotech Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Inventories, Finished Goods Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Finished Goods
Get a 7-Day Free Trial 130.89 170.39 217.51 451.66 381.85

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 451.66 0.00 0.00 0.00 381.85
NSE:WINDLAS
90GF Score
Windlas Biotech Ltd NSE:WINDLAS
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ₹382 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Inventories, Finished Goods of ₹382 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's Inventories, Finished Goods too high?
Windlas Biotech's current Inventories, Finished Goods is ₹382 Mil. Overall, Windlas Biotech has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Inventories, Finished Goods compare to ZTS and UTHR?
Windlas Biotech's Inventories, Finished Goods of ₹382 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current Inventories, Finished Goods is ₹382 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹940.70, compared to a current price of ₹852.25 — trading 9.4% below its estimated fair value. The current Inventories, Finished Goods is ₹382 Mil. Windlas Biotech's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Inventories, Finished Goods is ₹382 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹852.25 is trading 9.4% below its estimated GF Value™ of ₹940.70. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Inventories, Finished Goods: ₹382 Mil
  • GF Value™: ₹940.70 vs. price of ₹852.25 (9.4% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
90GF Score

Get the complete analysis for NSE:WINDLAS

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹852.25
Price
₹940.70
GF Value